好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Facial Onset Sensory-Motor Neuronopathy: A Series of Two Cases Illustrating a Disease Spectrum
Neuromuscular and Clinical Neurophysiology (EMG)
P4 - Poster Session 4 (5:30 PM-6:30 PM)
12-028

The purpose of this case series is to add to the growing literature on Facial Onset Sensory-Motor Neuronopathy (FOSMN) syndrome and explore early signs of this challenging diagnosis.


First described in 2006 as a novel syringomyelia-like syndrome, there are now at least 47 reported cases of FOSMN reported globally. FOSMN is thought to be a neurodegenerative syndrome that starts with sensory neuron loss in the trigeminal nerve distribution followed by rostral to caudal progression of sensory loss.  It often involves bulbar muscle weakness, with dysphagia and dysarthria, as well as facial muscle weakness. Cramps, fasciculations and upper extremity weakness tend to occur later in the disease course. Here, we describe two cases of FOSMN that were diagnosed at our institution and had varied disease progression.


A case series of two individuals with FOSMN is presented. We report the clinical, laboratory, imaging and neurophysiologic findings. Both patients were male and had symptom onset in their 6th decade of life. The first symptom was unilateral perioral numbness and paresthesias for both patients.  Sensory presentation varied markedly, with one having focal facial numbness, and the other having symptoms spreading to the scalp, neck, trunk and upper limbs. Bulbar involvement was seen early on and prominently in one patient while it was only minimal in the other. Electromyography showed active denervation in multiple muscle groups, reduced sensory nerve action potentials, and absent blink reflexes in both patients. MRI of the cervical spine showed cord atrophy. One patient was treated with IVIg but still progressed to PEG tube dependency, while the other did not receive treatment.


NA

FOSMN syndrome is a challenging and rare syndrome.  Diagnosis depends on the characteristic clinical presentation of facial onset sensory loss and facial weakness in conjunction with electro- diagnostic testing showing sensory and motor neuronopathy, which is typically more severe rostrally, and exhibits absent or abnormal blink reflexes.


Authors/Disclosures
Rabia Yasin, MD
PRESENTER
Dr. Yasin has nothing to disclose.
Amro Stino, MD (Michigan Medicine - University of Michigan) Dr. Stino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CSL Behring. Dr. Stino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Stino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Stino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Stino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexon. The institution of Dr. Stino has received research support from GBS-CIDP Foundation. The institution of Dr. Stino has received research support from Bristol Myers Squibb.
Adam Quick, MD (The Ohio State University) The institution of Dr. Quick has received research support from NINDS. The institution of Dr. Quick has received research support from NEALS.
Chad Hoyle, MD (Ohio State University) Dr. Hoyle has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for National Football League. Dr. Hoyle has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avexis. Dr. Hoyle has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Reata. The institution of Dr. Hoyle has received research support from REATA. The institution of Dr. Hoyle has received research support from TAKEDA.
William D. Arnold, MD Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for La Hoffmann Roche. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadent Therapeutics . Dr. Arnold has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Arnold has received research support from NIH. The institution of Dr. Arnold has received research support from NMD Pharma. The institution of Dr. Arnold has received research support from Gilead Sciences. The institution of Dr. Arnold has received research support from CureSMA. Dr. Arnold has received intellectual property interests from a discovery or technology relating to health care.
Samantha J. LoRusso, MD (Kaiser) Dr. LoRusso has nothing to disclose.
Stephen J. Kolb, MD, PhD (The Ohio State University) Dr. Kolb has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AveXis. Dr. Kolb has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for CureSMA. The institution of Dr. Kolb has received research support from NIH. The institution of Dr. Kolb has received research support from AveXis. The institution of Dr. Kolb has received research support from NIH.